Literature DB >> 21319865

Drugs in development for viral hepatitis: care and caution.

Paul J Pockros.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21319865     DOI： 10.2165/11587090-000000000-00000

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  10 in total

Review 1.  A perspective on modelling hepatitis C virus infection.

Authors:  J Guedj; L Rong; H Dahari; A S Perelson
Journal:  J Viral Hepat       Date:  2010-08-15       Impact factor: 3.728

2.  Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C.

Authors:  Patrick Marcellin; Xavier Forns; Tobias Goeser; Peter Ferenci; Frederik Nevens; Giampiero Carosi; Joost P Drenth; Lawrence Serfaty; Koen De Backer; Rolf Van Heeswijk; Donghan Luo; Gaston Picchio; Maria Beumont
Journal:  Gastroenterology       Date:  2010-10-26       Impact factor: 22.682

Review 3.  Resistance to direct antiviral agents in patients with hepatitis C virus infection.

Authors:  Christoph Sarrazin; Stefan Zeuzem
Journal:  Gastroenterology       Date:  2009-12-16       Impact factor: 22.682

4.  Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotype.

Authors:  Alexander J Thompson; Andrew J Muir; Mark S Sulkowski; Keyur Patel; Hans L Tillmann; Paul J Clark; Susanna Naggie; Jacques Fellay; Dongliang Ge; Jeanette J McCarthy; David B Goldstein; John G McHutchison
Journal:  Hepatology       Date:  2010-06-30       Impact factor: 17.425

5.  Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction.

Authors:  Alexander J Thompson; Jacques Fellay; Keyur Patel; Hans L Tillmann; Susanna Naggie; Dongliang Ge; Thomas J Urban; Kevin V Shianna; Andrew J Muir; Michael W Fried; Nezam H Afdhal; David B Goldstein; John G McHutchison
Journal:  Gastroenterology       Date:  2010-06-12       Impact factor: 22.682

6.  Telaprevir for previously treated chronic HCV infection.

Authors:  John G McHutchison; Michael P Manns; Andrew J Muir; Norah A Terrault; Ira M Jacobson; Nezam H Afdhal; E Jenny Heathcote; Stefan Zeuzem; Hendrik W Reesink; Jyotsna Garg; Mohammad Bsharat; Shelley George; Robert S Kauffman; Nathalie Adda; Adrian M Di Bisceglie
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

Review 7.  Virology of hepatitis B and C viruses and antiviral targets.

Authors:  Jean-Michel Pawlotsky
Journal:  J Hepatol       Date:  2005-11-21       Impact factor: 25.083

8.  Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection.

Authors:  Jason Grebely; Kathy Petoumenos; Margaret Hellard; Gail V Matthews; Vijayaprakash Suppiah; Tanya Applegate; Barbara Yeung; Phillipa Marks; William Rawlinson; Andrew R Lloyd; David Booth; John M Kaldor; Jacob George; Gregory J Dore
Journal:  Hepatology       Date:  2010-10       Impact factor: 17.425

9.  Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial.

Authors:  Edward J Gane; Stuart K Roberts; Catherine A M Stedman; Peter W Angus; Brett Ritchie; Rob Elston; David Ipe; Peter N Morcos; Linda Baher; Isabel Najera; Tom Chu; Uri Lopatin; M Michelle Berrey; William Bradford; Mark Laughlin; Nancy S Shulman; Patrick F Smith
Journal:  Lancet       Date:  2010-10-14       Impact factor: 79.321

10.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.

Authors:  Dongliang Ge; Jacques Fellay; Alexander J Thompson; Jason S Simon; Kevin V Shianna; Thomas J Urban; Erin L Heinzen; Ping Qiu; Arthur H Bertelsen; Andrew J Muir; Mark Sulkowski; John G McHutchison; David B Goldstein
Journal:  Nature       Date:  2009-08-16       Impact factor: 49.962
  10 in total
  2 in total

Review 1.  Interferon-free hepatitis C therapy: how close are we?

Authors:  Paul J Pockros
Journal:  Drugs       Date:  2012-10-01       Impact factor: 9.546

Review 2.  Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C.

Authors:  Caroline M Perry
Journal:  Drugs       Date:  2012-03-26       Impact factor: 9.546
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.